250
Participants
Start Date
November 30, 2011
Primary Completion Date
October 31, 2013
Study Completion Date
February 28, 2015
Simtuzumab
Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
Gemcitabine
Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
Placebo to match simtuzumab
Placebo to match simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
Saint Luke's-Roosevelt Hospital Center, New York
PinnacleHealth, Harrisburg
Abington Hematology Oncology Associates, Inc., Willow Grove
Georgia Cancer Specialists, P.C., Atlanta
Florida Cancer Specialists, Tampa
University of South Alabama Mitchell Cancer Institute, Mobile
Tennessee Oncology, PLLC, Nashville
Oncology Hematology Care, Inc., Crestview Hills
Oncology Hematology Care, Inc., Blue Ash
Providence Cancer Center Oncology and Hematology Care Clinic-Eastside Portland, Southfield
Washington University School of Medicine, St Louis
San Antonio Military Medical Center, Fort Sam Houston
Utah Cancer Specialists, Salt Lake City
Wilshire Oncology Medical Group, Inc., Rancho Cucamonga
Sharp Health Care, San Diego
California Cancer Associates for Research and Excellence (CCARE), Fresno
San Jose Medical Group, San Jose
Blokhin Cancer Research Center of Russia, Dept. of clinical pharmacology, Moscow
"State Institution Blokhin Cancer Research Centre RAMS", Moscow
"Non-State Institution of healthcare Central Clinical Hospital #1 OAO RZD", Moscow
"Non-state Healthcare Institution N.A. Semashko Central Clinical Hospital #2 of JSC Russian Railway", Moscow
Regional Oncology Dispensary, Ivanovo
"State Institution of Healthcare Arkhangelsk Regional Clinical Oncology Dispensary", Arkhangelsk
Petrov Research Oncology Institute, Saint Petersburg
Medical Radiological Research Center of Russian Academy of Medical Sciences, Obninsk, Obninsk
Kursk Regional Oncologic Dispensary, Kursk
Republican Clinical Oncologic Dispensary of Ministry of health of Republic Tatarstan, Kazan'
Republic Clinical Oncology Dispensary of the Ministry of Healthcare of Republic of Bashkortostan, Ufa
"State Budgetary Healthcare Institution Nizhny Novgorod Regional Oncological Dispensary", Nizhny Novgorod
"Budgetary Healthcare Institution of Omsk Region Clinical Oncologic Dispensary", Omsk
Birmingham Hematology and Oncology Associates, LLC, Birmingham
Central Hematology Oncology Medical Group, Inc., Alhambra
Comprehensive Blood and Cancer Center, Bakersfield
Anne Arundel Medical Center, Annapolis Oncology Center, Annapolis
West Michigan Cancer Center, Kalamazoo
Pacific Shores Medical Group, Long Beach
UCLA Community Oncology Practice, Los Angeles
Stanford University Medical Center, Palo Alto
Saint Mary's Regional Cancer Center, Grand Junction
Hematology Oncology Associates, PC, Stamford
Northwestern University, Chicago
Hematology and Oncology Associates at BridgePoint, Tupelo
Saint Joseph Oncology, Inc., Saint Joseph
Montana Cancer Institute Foundation c/o Montana Cancer Specialists, Missoula
Comprehensive Cancer Centers of Nevada, Henderson
Beth Israel Comprehensive Cancer Center, New York
Duke University Medical Center, Comprehensive Cancer Center, Durham
Emerywood Hematology and Oncology, High Point
Charleston Hematology Oncology Associates, PA, Charleston
South Carolina Oncology Associates, Columbia
Tennessee Cancer Specialists, Knoxville
Coastal Bend Cancer Center, Corpus Christi
University of Texas Southwestern Medical Center at Dallas, Dallas
Center for Cancer and Blood Disorders, PC, Fort Worth
Joe Arrington Cancer Research and Treatment Center, Lubbock
Virginia Cancer Specialists, PC, Fairfax
Virginia Cancer Institute, Richmond
Lead Sponsor
Gilead Sciences
INDUSTRY